Neurologist visit frequency was modestly higher among cancer cases than controls but declined over time in both settings, ...

A study suggests vitamin D may reduce long COVID symptoms at 8 weeks, although larger trials are needed to confirm benefits ...

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and ...

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can ...

Capping Medicare beneficiaries’ monthly insulin out-of-pocket costs at $35 was associated with steep reductions in spending ...

ATTAIN demonstrated placebo-adjusted weight reductions of roughly 9–11 percentage points at 72 weeks, with 27.3 lb (12.4%) ...

Federal pharmacy benefit manager transparency reforms must contend with concentrated pharmaceutical markets that lack ...

The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies.

Price variation does not just occur across markets and services; it also emerges between networks and providers.

Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP ...

HB 4965 permits switching to an alternative medically appropriate treatment of equal or lesser value after initial approval, ...

Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients ...